<DOC>
	<DOCNO>NCT01313065</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability IV administration VX15/2503 patient advance solid tumor . The escalation part study determine maximum tolerate dose ( MTD ) .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , PK &amp; PD Intravenous VX15/2503 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>VX15/2503-01 dose-escalation , open label study evaluate safety tolerability IV administer VX15/2503 patient advance solid tumor . This accomplish use dose escalation procedure start low dos VX15/2503 continue base predefined parameter maximum tolerate dose identify . The study drug , VX15/2503 , monoclonal antibody bind semaphorin 4D ( SEMA4D ; CD100 ) antigen . Semaphorins show play important role certain physiological process vascular growth , tumor progression immune cell regulation . Experimental evidence suggest SEMA4D two mechanism action result angiogenesis tumor proliferation invasion . Antibody neutralization SEMA4D thus may represent new therapeutic strategy cancer treatment .</detailed_description>
	<criteria>Main Patients 18 yrs old confirm histological cytological advance solid tumor , relapse refractory standard treatment curative therapy available ; patient must demonstrate progressive disease prior entry Has measurable disease define RECIST1.1 Life expectancy least 3 month ( per investigator assessment ) ECOG performance status 02 Adequate bone marrow , renal liver function Recovered significant prior toxicity previous antineoplastic therapy For patient reproductive potential , willing use medically acceptable form contraception throughout study period least 4 week last dose VX15/2503 Expansion cohort patient cohort must one follow characteristic : A diagnosis pancreatic neuroendocrine tumor OR A diagnosis soft tissue sarcoma OR A diagnosis bone metastasis OR A diagnosis advance solid tumor AND T cell count least 1500 cells/uL OR B cell count least 250 cells/uL screen Main Treatment antineoplastic agent ( chemotherapy , immunotherapy , radiotherapy endocrine therapy ) within 3 week prior start study treatment Treatment investigational agent within 4 week prior start study treatment Is concurrent antineoplastic therapy exception continue luteinizing hormonereleasing hormone agonist/antagonist therapy patient castrateresistant prostate cancer Treatment oral parenteral corticosteroid excess 10mg/day prednisolone equivalent 5 day within 4 week prior start study treatment requirement systemic immunosuppressive therapy reason Untreated brain Mets CNS tumor involvement Any intercurrent illness condition could impact patient compliance ability complete study Sensitivity VX15/2503 ingredients excipients VX15/2503 Pregnant breastfeed woman ( woman childbearing potential must negative serum pregnancy test within 3 day prior receive first dose VX15/2503 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>VX15/2503</keyword>
	<keyword>Semaphorin 4D</keyword>
	<keyword>SEMA4D</keyword>
	<keyword>CD100</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>